Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA

Journal of General Virology

Volumn 89, Issue 9, 2008, Pages 2252-2261

  Nazari, Reza ^a   Ma, Xue Zhong ^a   Joshi, Sadhna ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HAMMERHEAD RIBOZYME; MESSENGER RNA; VIRUS DNA; VIRUS VECTOR; RIBOZYME; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RIBOZYME THERAPY; STEM CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENTRY; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CELL LINE; ENZYMOLOGY; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; VIROLOGY; VIRUS GENE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DNA, VIRAL; GENE EXPRESSION; GENES, VIRAL; GENETIC VECTORS; HIV-1; HUMANS; MICE; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; RNA, CATALYTIC; RNA, MESSENGER; RNA, VIRAL; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION;

EID: 52649126669     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/001222-0     Document Type: Article

References (39)

1. Adachi, A., Gendelman, H. E., Koenig, S., Folks, T.,Willey, R., Rabson, A. & Martin, M. A. (1986). Production of acquired immunodefiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59, 284-291.
2. + hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1, 244-254.
3. Bai, J., Rossi, J. J. & Akkina, R. (2001). Multivalent anti-CCR5 ribozymes for stem cell-based HIV-1 gene therapy. AIDS Res Hum Retroviruses 17, 385-399.
4. Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J. & Weiss, R. A. (1998). A new classification for HIV-1. Nature 391, 240-245.
5. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. (1993). VSV-G glycoprotein pseudotyped retroviral vectors: concentration to very high titre and efficient gene transfer into mammalian and non-mammalian cells. Proc Natl Acad Sci U S A 90, 8033-8037.
6. Cagnon, L. & Rossi, J. (2000). Downregulation of the CCR5 β chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucleic Acid Drug Dev 10, 251-261.
7. Cheng, L., Du, C., Murray, D., Tong, X., Zhang, Y. A., Chen, B. P. & Hawley, R. G. (1997). A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther 4, 1013-1022.
8. De Clercq, E. (2000). Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 57, 833-839.
9. Dean, M., Carrington, M., Winkler, C., Huttley, G. A., Smith, M. W., Allikmets, R., Goedert, J. J., Buchbinder, S. P., Vittinghoff, E. & other authors (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862.
10. Gartner, S., Markovits, P., Markovitz, D. M., Kaplan, M. H., Gallo, R. C. & Popovic, P. (1986). The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219.
11. Hawley, R. G. (1994). High-titer retroviral vectors for efficient transduction of functional genes into murine hematopoietic stem cells. Ann N Y Acad Sci 716, 327-330.
12. Huang, Y., Paxton, W. A., Wolinsky, S. M., Neumann, A. U., Zhang, L., He, T., Kang, S., Ceradini, D., Jin, Z. & other authors (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2, 1240-1243.
13. Jeang, K. T. & Berkhout, B. (1992). Kinetics of HIV-1 long terminal repeat trans-activation. Use of intragenic ribozyme to assess rate-limiting steps. J Biol Chem 267, 17891-17892.
14. Kawabata, K., Ujikawa, M., Egawa, T., Kawamoto, H., Tachibana, K., Iizasa, H., Katsura, Y., Kishimoto, T. & Nagasawa, T. (1999). A cell autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci U S A 96, 5663-5667.
15. Lamothe, B. & Joshi, S. (2000). Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Front Biosci 5, D527-D555.
16. Li, M. J., Bauer, G., Michienzi, A., Yee, J. K., Lee, N. S., Kim, J., Li, S., Castanotto, D., Zaia, J. & Rossi, J. J. (2003). Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8, 196-206.
17. Li, M. J., Kim, J., Li, S., Zaia, J., Yee, J. K., Anderson, J., Akkina, R. & Rossi, J. J. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12, 900-909.
18. Li, W., Yu, M., Bai, L., Bu, D. & Xu, X. (2006). Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells. J Acquir Immune Defic Syndr 43, 516-522.
19. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A. & Landau, N. R. (1996). Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86, 367-377.
20. Martinez, M. A., Gutierrez, A., Armand-Ugon, M., Blanco, J., Parera, M., Gomez, J., Clotet, B. & Este, J. A. (2002). Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16, 2385-2390.
21. Lys-based hammerhead ribozymes. Nucleic Acids Res 27, 1698-1708.
22. Michael, N. L., Louie, L. G. & Sheppard, H. W. (1997). CCR5Δ32 gene deletion in HIV-1 infected patients. Lancet 350, 741-742.
23. Miller, A. D. & Buttimore, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6, 2895-2902.
24. Mok, H. P., Javed, S. & Lever, A. (2007). Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority. Gene Ther 14, 741-751.
25. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
26. Onai, N., Zhang, Y., Yoneyama, H., Kitamura, T., Ishikawa, S. & Matsushima, K. (2000). Impairment of lymphopoiesis and myelopoiesis in mice reconstituted with bone marrow-hematopoietic progenitor cells expressing SDF-1-intrakine. Blood 96, 2074-2080.
27. Pannell, D. & Ellis, J. (2001). Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 11, 205-217.
28. Qin, X. F., An, D. S., Chen, I. S. & Baltimore, D. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 100, 183-188.
29. Ramezani, A. & Joshi, S. (1996). Comparative analysis of five highly conserved sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Antisense Nucleic Acid Drug Dev 6, 229-235.
30. Ramezani, A., Ding, S. F. & Joshi, S. (1997). Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther 4, 861-867.
31. Ramezani, A., Hawley, T. S. & Hawley, R. G. (2000). Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2, 458-469.
32. Ramezani, A., Ma, X. Z., Nazari, R. & Joshi, S. (2002). Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Front Biosci 7, a29-a36.
33. Rossi, J. J. (1999). The application of ribozymes to HIV infection. Curr Opin Mol Ther 1, 316-322.
34. Rossi, J. J., June, C. H. & Kohn, D. B. (2007). Genetic therapies against HIV-1. Nat Biotechnol 25, 1444-1454.
35. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
36. Sheppard, H. W., Celum, C., Michael, N. L., O'Brien, S., Dean, M., Carrington, M., Dondero, D. & Buchbinder, S. P. (2002). HIV-1 infection in individuals with the CCR5-D32/D32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 29, 307-313.
37. Shiota, M., Sano, M., Miyagishi, M. & Taira, K. (2004). Ribozymes: applications to functional analysis and gene discovery. J Biochem 136, 133-147.
38. Strayer, D. S., Akkina, R., Bunnell, B. A., Dropulic, B., Planelles, V., Pomerantz, R. J., Rossi, J. J. & Zaia, J. A. (2005). Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11, 823-842.
39. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. (1998). Function of the chemokine receptor CXCR4 in hematopoietic and in cerebellar development. Nature 393, 595-599.